

within two months of the mailing of the final Office Action, *i.e.*, on or before February 10, 2003, in order to provoke an Advisory Action.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to this document, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski Account L.L.P. No.: 50-1212/10006736.

Reconsideration of the application in view of the following amendments and remarks is respectfully requested.

#### AMENDMENT

Please cancel claims 8 without prejudice or disclaimer.

Please amend the claims to read as follows:

---

C1 1. (Three times amended) A method for reducing the number of metastases in an animal exhibiting a primary tumor comprising administering to said animal a dose of 10 mg/kg to 150 mg/kg of an aminoalkylphosphorothioate or active metabolite thereof, wherein the number of metastases is reduced.

---

9. (Three times amended) The method claim 1, wherein said aminoalkylphosphorothioate is the thiol form.

C2 10. (Three times amended) The method claim 1, wherein said aminoalkylphosphorothioate is the disulfide form.

11. (Twice amended) The method of claim 1, wherein said aminoalkylphosphorothioate or active metabolite thereof is selected from the group consisting of WR-2721 (amifostine), WR-1065, WR-638, WR-77913, WR-33278, WR-3689, WR-2822, WR-2529, WR-255591, WR-2823, WR-255709, WR-151326 and WR-151327.

12. (Twice amended) The method of claim 1, wherein the route of administration of said aminoalkylphosphorothioate or active metabolite thereof is intravenous, intraperitoneal, intradermal, intramuscular, dermal, nasal, buccal, rectal, vaginal, inhalation, or topical.

C2  
Cont

13. (Twice amended) The method of claim 1, wherein said aminoalkylphosphorothioate or active metabolite thereof is formulated into solutions, suspensions, tablets, pills, capsules, sustained release formulations, powders, creams, ointments, salves, sprays, pumps, liposomes, suppositories, inhalers, and patches.

---

C3

23. (Amended) The method of claim 1, further comprising monitoring the ability of the dose of a aminoalkylphosphorothioate or active metabolite to reduce metastases in the animal.

---

C4

30. (Three times amended) A method for inhibiting metastasis in an animal exhibiting a primary tumor comprising administering to said animal a dose of 10 mg/kg to 150 mg/kg of an aminoalkylphosphorothioate or active metabolite thereof, wherein the number of metastases is inhibited.

31. (Three times amended) A method for preventing metastasis in an animal exhibiting a primary tumor comprising administering to said animal a dose of 10 mg/kg to 150 mg/kg of an aminoalkylphosphorothioate or active metabolite thereof, and wherein metastases are prevented in said animal.

32. (Amended) The method of claim 11, wherein said aminoalkylphosphorothioate or active metabolite thereof is WR-2721.

33. (Amended) The method of claim 11, wherein said aminoalkylphosphorothioate or active metabolite thereof is WR-1065.

---